Last reviewed 2026-04-20 · How we verify

Artificial tears eye-drops

Artificial tears eye-drops, marketed by Hotel Dieu de France Hospital, hold a position in the over-the-counter ophthalmic market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market presence. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
• SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
• A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
• A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
• FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
• A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
• Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
• Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.